These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 22537769)

  • 1. KGA-2727, a novel selective inhibitor of a high-affinity sodium glucose cotransporter (SGLT1), exhibits antidiabetic efficacy in rodent models.
    Shibazaki T; Tomae M; Ishikawa-Takemura Y; Fushimi N; Itoh F; Yamada M; Isaji M
    J Pharmacol Exp Ther; 2012 Aug; 342(2):288-96. PubMed ID: 22537769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intestinal Sodium Glucose Cotransporter 1 Inhibition Enhances Glucagon-Like Peptide-1 Secretion in Normal and Diabetic Rodents.
    Oguma T; Nakayama K; Kuriyama C; Matsushita Y; Yoshida K; Hikida K; Obokata N; Tsuda-Tsukimoto M; Saito A; Arakawa K; Ueta K; Shiotani M
    J Pharmacol Exp Ther; 2015 Sep; 354(3):279-89. PubMed ID: 26105952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SHR3824, a novel selective inhibitor of renal sodium glucose cotransporter 2, exhibits antidiabetic efficacy in rodent models.
    Yan PK; Zhang LN; Feng Y; Qu H; Qin L; Zhang LS; Leng Y
    Acta Pharmacol Sin; 2014 May; 35(5):613-24. PubMed ID: 24786232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective sodium-dependent glucose transporter 1 inhibitors block glucose absorption and impair glucose-dependent insulinotropic peptide release.
    Dobbins RL; Greenway FL; Chen L; Liu Y; Breed SL; Andrews SM; Wald JA; Walker A; Smith CD
    Am J Physiol Gastrointest Liver Physiol; 2015 Jun; 308(11):G946-54. PubMed ID: 25767259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of the effect of canagliflozin on renal glucose reabsorption and progression of hyperglycemia in zucker diabetic Fatty rats.
    Kuriyama C; Xu JZ; Lee SP; Qi J; Kimata H; Kakimoto T; Nakayama K; Watanabe Y; Taniuchi N; Hikida K; Matsushita Y; Arakawa K; Saito A; Ueta K; Shiotani M
    J Pharmacol Exp Ther; 2014 Nov; 351(2):423-31. PubMed ID: 25216746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models.
    Fujimori Y; Katsuno K; Nakashima I; Ishikawa-Takemura Y; Fujikura H; Isaji M
    J Pharmacol Exp Ther; 2008 Oct; 327(1):268-76. PubMed ID: 18583547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SGL5213, a novel and potent intestinal SGLT1 inhibitor, suppresses intestinal glucose absorption and enhances plasma GLP-1 and GLP-2 secretion in rats.
    Io F; Gunji E; Koretsune H; Kato K; Sugisaki-Kitano M; Okumura-Kitajima L; Kimura K; Uchida S; Yamamoto K
    Eur J Pharmacol; 2019 Jun; 853():136-144. PubMed ID: 30878385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti-hyperglycaemic activity.
    Yamamoto K; Uchida S; Kitano K; Fukuhara N; Okumura-Kitajima L; Gunji E; Kozakai A; Tomoike H; Kojima N; Asami J; Toyoda H; Arai M; Takahashi T; Takahashi K
    Br J Pharmacol; 2011 Sep; 164(1):181-91. PubMed ID: 21410690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-activity relationship studies of 4-benzyl-1H-pyrazol-3-yl β-d-glucopyranoside derivatives as potent and selective sodium glucose co-transporter 1 (SGLT1) inhibitors with therapeutic activity on postprandial hyperglycemia.
    Fushimi N; Fujikura H; Shiohara H; Teranishi H; Shimizu K; Yonekubo S; Ohno K; Miyagi T; Itoh F; Shibazaki T; Tomae M; Ishikawa-Takemura Y; Nakabayashi T; Kamada N; Ozawa T; Kobayashi S; Isaji M
    Bioorg Med Chem; 2012 Nov; 20(22):6598-612. PubMed ID: 23062824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats.
    Fujimori Y; Katsuno K; Ojima K; Nakashima I; Nakano S; Ishikawa-Takemura Y; Kusama H; Isaji M
    Eur J Pharmacol; 2009 May; 609(1-3):148-54. PubMed ID: 19281809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice.
    Suzuki M; Honda K; Fukazawa M; Ozawa K; Hagita H; Kawai T; Takeda M; Yata T; Kawai M; Fukuzawa T; Kobayashi T; Sato T; Kawabe Y; Ikeda S
    J Pharmacol Exp Ther; 2012 Jun; 341(3):692-701. PubMed ID: 22410641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels.
    Suga T; Kikuchi O; Kobayashi M; Matsui S; Yokota-Hashimoto H; Wada E; Kohno D; Sasaki T; Takeuchi K; Kakizaki S; Yamada M; Kitamura T
    Mol Metab; 2019 Jan; 19():1-12. PubMed ID: 30416006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pretreatment with KGA-2727, a selective SGLT1 inhibitor, is protective against myocardial infarction-induced ventricular remodeling and heart failure in mice.
    Sawa Y; Saito M; Ishida N; Ibi M; Matsushita N; Morino Y; Taira E; Hirose M
    J Pharmacol Sci; 2020 Jan; 142(1):16-25. PubMed ID: 31776072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models.
    Liang Y; Arakawa K; Ueta K; Matsushita Y; Kuriyama C; Martin T; Du F; Liu Y; Xu J; Conway B; Conway J; Polidori D; Ways K; Demarest K
    PLoS One; 2012; 7(2):e30555. PubMed ID: 22355316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LX4211 increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium/glucose cotransporter 1 (SGLT1)-mediated absorption of intestinal glucose.
    Powell DR; Smith M; Greer J; Harris A; Zhao S; DaCosta C; Mseeh F; Shadoan MK; Sands A; Zambrowicz B; Ding ZM
    J Pharmacol Exp Ther; 2013 May; 345(2):250-9. PubMed ID: 23487174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of combined treatment with canagliflozin and teneligliptin on glucose intolerance in Zucker diabetic fatty rats.
    Oguma T; Kuriyama C; Nakayama K; Matsushita Y; Yoshida K; Kiuchi S; Ikenaga Y; Nakamaru Y; Hikida K; Saito A; Arakawa K; Oka K; Ueta K; Shiotani M
    J Pharmacol Sci; 2015 Apr; 127(4):456-61. PubMed ID: 25892328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of sodium-glucose cotransporter 1 ameliorates hyperglycemia by mediating incretin secretion in mice.
    Moriya R; Shirakura T; Ito J; Mashiko S; Seo T
    Am J Physiol Endocrinol Metab; 2009 Dec; 297(6):E1358-65. PubMed ID: 19808907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo.
    Tahara A; Kurosaki E; Yokono M; Yamajuku D; Kihara R; Hayashizaki Y; Takasu T; Imamura M; Qun L; Tomiyama H; Kobayashi Y; Noda A; Sasamata M; Shibasaki M
    Naunyn Schmiedebergs Arch Pharmacol; 2012 Apr; 385(4):423-36. PubMed ID: 22139434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level.
    Katsuno K; Fujimori Y; Takemura Y; Hiratochi M; Itoh F; Komatsu Y; Fujikura H; Isaji M
    J Pharmacol Exp Ther; 2007 Jan; 320(1):323-30. PubMed ID: 17050778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Macula Densa SGLT1-NOS1-Tubuloglomerular Feedback Pathway, a New Mechanism for Glomerular Hyperfiltration during Hyperglycemia.
    Zhang J; Wei J; Jiang S; Xu L; Wang L; Cheng F; Buggs J; Koepsell H; Vallon V; Liu R
    J Am Soc Nephrol; 2019 Apr; 30(4):578-593. PubMed ID: 30867247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.